The company proposes to set up manufacturing facilities for an aggregate installed annual capacity of 710 kgs bulk active pharmaceutical ingredients of high value biopharmaceuticals - Tacrolimus, Daunomycin and Hyaluronic acid (Pharma grade).
A number of other products like Rapamycin, Mycophenolic acid, Clavulenic acid, Vancomycin and Monoclonal antibodies (anti-cancer), and their formulations will be introduced in phases.
Products: Installed Capacities
|Hyaluronic Acid – Pharma
|Total Installed capacity